{"id":37114,"date":"2026-03-23T12:57:38","date_gmt":"2026-03-23T12:57:38","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/37114\/"},"modified":"2026-03-23T12:57:38","modified_gmt":"2026-03-23T12:57:38","slug":"roche-petrelintide-data-recasts-obesity-opportunity-and-pipeline-growth-story","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/37114\/","title":{"rendered":"Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.<\/p>\n

Roche Holding (SWX:ROG) reported highly positive Phase II results for its amylin analogue petrelintide in the ZUPREME-1 trial.<\/p>\n

The drug, co-developed with Zealand Pharma, achieved clinically meaningful and sustained weight loss in people living with overweight and obesity.<\/p>\n

Petrelintide showed a favorable tolerability profile, including fewer gastrointestinal side effects compared to placebo.<\/p>\n

The data support Roche\u2019s plans for late-stage development and potential combination obesity therapies.<\/p>\n

For investors watching the growing obesity drug space, this update puts Roche Holding (SWX:ROG) more clearly on the map. The shares most recently traded at CHF341.2, with a 1 year return of 14.7% and a 3 year return of 44.1%. Those figures come in a context where Roche has been viewed primarily as a large, diversified pharma group rather than a pure play obesity name.<\/p>\n

The new petrelintide data could influence how the market thinks about Roche\u2019s future mix of growth drivers, especially if late stage studies confirm both efficacy and tolerability. As you weigh this news, the key questions will be how quickly Roche can move into Phase III, what the combination therapy roadmap looks like, and how this obesity program might sit alongside the company\u2019s broader pipeline.<\/p>\n

Stay updated on the most important news stories for Roche Holding<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Roche Holding.<\/p>\n

\"SWX:ROG<\/a> SWX:ROG Earnings & Revenue Growth as at Mar 2026 <\/p>\n

4 things going right for Roche Holding that this headline doesn’t cover.<\/a><\/p>\n

For Roche, petrelintide looks less like a standalone obesity blockbuster and more like a building block for a broader metabolic franchise. The Phase II data show up to 10.7% mean weight loss at 42 weeks with tolerability that is comparable to placebo, including very low vomiting rates in the maximally effective arm. That profile may matter in a market where injectable GLP\u20111 drugs from Novo Nordisk and Eli Lilly already set a high bar on efficacy but often come with gastrointestinal side effects. For you as an investor, the key angle is that Roche now has two obesity assets with positive mid\u2011stage data, petrelintide and CT\u2011388. Together, these could open different treatment options across monotherapy and combinations.<\/p>\n

This news supports the view that Roche\u2019s pipeline in high value biologics is progressing, adding another potential growth driver alongside existing oncology, immunology and neurology programs.<\/p>\n

It also tests the narrative that R&D setbacks are a major overhang, because investors will be watching whether petrelintide can move through late stage trials without repeating the mixed outcomes seen in some other Roche studies.<\/p>\n

The obesity focus and co development with Zealand Pharma are not fully reflected in older narratives that lean heavily on diagnostics and oncology, so the potential revenue mix shift toward metabolic disease may be underappreciated.<\/p>\n

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Roche Holding<\/a> to help decide what it’s worth to you.<\/p>\n

\u26a0\ufe0f The obesity drug market is highly competitive, with established products from Novo Nordisk and Eli Lilly already widely used, so petrelintide will need clear points of differentiation to win share.<\/p>\n

\u26a0\ufe0f Roche still faces late stage trial risk, including for petrelintide combinations, and analysts have flagged that R&D setbacks can affect confidence in future earnings.<\/p>\n

\ud83c\udf81 Positive Phase II data for both petrelintide and CT\u2011388 give Roche multiple shots in a large therapy area, which could broaden its set of potential growth drivers.<\/p>\n

\ud83c\udf81 The tolerability profile in ZUPREME\u20111, with discontinuation rates similar to placebo and mainly mild gastrointestinal effects, may appeal to patients who struggle with side effects on existing obesity drugs.<\/p>\n

From here, you may want to watch how quickly Roche locks in Phase III designs for petrelintide, how regulators and clinicians react to the full ZUPREME\u20111 dataset once it is presented, and whether ZUPREME\u20112 in people with type 2 diabetes shows a similar balance of efficacy and tolerability. Progress on the planned petrelintide plus CT\u2011388 combination study later in 2026 will also be a key signal of how Roche intends to compete with established obesity players. Any management commentary on where obesity could sit in Roche\u2019s overall revenue mix can help you judge how material this program might become over time.<\/p>\n

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Roche Holding, head to the community page for Roche Holding<\/a> to never miss an update on the top community narratives.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ROG.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":18683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[21852,1813,134,994,6293,7119],"class_list":{"0":"post-37114","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-gastrointestinal-side-effects","9":"tag-obesity","10":"tag-roche","11":"tag-roche-holding","12":"tag-tolerability-profile","13":"tag-zealand-pharma"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116278607305436678","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/37114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=37114"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/37114\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=37114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=37114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=37114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}